Genesis Genomics Pockets $306K to Develop Cancer Dx | GenomeWeb
NEW YORK (GenomeWeb News) - Genesis Genomics has received a CAN$311,735 (US$ 305,540) investment from the Ontario provincial government to fund its mitochondrial DNA-based diagnostic tests for cancer, the firm’s controller, Carole McCollum, told GenomeWeb News today.
The Thunder Bay, Ontario-based company will use the funds from the Northern Ontario Heritage Fund to continue to develop and commercialize a diagnostic test for prostate cancer and to develop an early-stage breast cancer test, McCollum said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.